What insider share transactions did GSK (GSK) report in this 6-K?

GSK reported that multiple senior managers and one closely associated person acquired small amounts of ordinary shares through its Share Reward Plan. Each transaction involved 12 or 14 shares per person, all executed on 9 June 2026 on the London Stock Exchange.

Which GSK (GSK) executives acquired shares under the Share Reward Plan?

Executives named include Lynn Baxter, Julie Brown, James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, and Victoria Whyte. Each participated in GSK’s Share Reward Plan, acquiring a modest number of ordinary shares as part of this routine employee share arrangement.

GSK (GSK) leaders receive shares under employee reward plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reports that several senior leaders and one person closely associated with a leader acquired small amounts of company stock through its Share Reward Plan. On 2026-06-09, each transaction involved GSK ordinary shares of 31 ¼ pence each, traded on the London Stock Exchange.

Executives including President Europe Lynn Baxter, Chief Financial Officer Julie Brown, and other senior leaders acquired either 14 or 12 ordinary shares each at a price of £18.8393 per share, split between partnership and matching shares. These are routine share plan acquisitions rather than open-market trades.

Key Figures

Share price: £18.8393 per share Individual award size: 14 ordinary shares Smaller individual award: 12 ordinary shares +3 more

6 metrics

Share price £18.8393 per share Price for all Share Reward Plan acquisitions on 2026-06-09

Individual award size 14 ordinary shares Aggregated volume for most named executives under Share Reward Plan

Smaller individual award 12 ordinary shares Aggregated volume for Victoria Whyte and Neil Falkingham

Transaction date 2026-06-09 Date all reported insider Share Reward Plan acquisitions occurred

Trading venue London Stock Exchange (XLON) Exchange where GSK ordinary share transactions were executed

Instrument nominal value 31 ¼ pence Nominal value of GSK ordinary shares acquired

Key Terms

PDMR, person closely associated, Share Reward Plan, Ordinary Shares, +2 more

6 terms

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

person closely associated regulatory

"Details of PDMR/person closely associated with them ('PCA')"

Ordinary Shares financial

"Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

ISIN financial

"ISIN: GB00BN7SWP63"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

LEI financial

"LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

06/11/2026 - 10:42 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	7 (partnership shares)
			£18.8393	7 (matching shares)

d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	6 (partnership shares)
			£18.8393	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.8393	6 (partnership shares)
			£18.8393	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £18.8393
e)	Date of the transaction	2026-06-09
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: June 11, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR

FAQ

At what price were the GSK (GSK) shares acquired by insiders?

All reported Share Reward Plan acquisitions were priced at £18.8393 per ordinary share. This single price applied to both partnership shares and matching shares for each participating executive and the person closely associated, across all transactions disclosed in the report.

How many GSK (GSK) shares did each executive obtain in these transactions?

Most named executives acquired an aggregated volume of 14 ordinary shares each, consisting of seven partnership shares and seven matching shares. Two individuals, Victoria Whyte and Neil Falkingham, acquired an aggregated 12 ordinary shares each, split evenly between partnership and matching shares.

Were these GSK (GSK) insider acquisitions open-market purchases?

No. The transactions are described as acquisitions of ordinary shares under GSK’s Share Reward Plan. That means the shares were received through an internal share plan structure, not as discretionary open-market purchases on the London Stock Exchange by the executives.

On what date and exchange did the GSK (GSK) insider transactions occur?

All disclosed acquisitions took place on 9 June 2026. The report specifies that each transaction in GSK ordinary shares of 31 ¼ pence nominal value was conducted on the London Stock Exchange, using its XLON market identifier code for the trading venue.